MENU
APR 7 - 8 2021

Advancing CGT: A GENEWIZ & Brooks Life Sciences Virtual Event

Accelerating Cell and Gene Therapy Treatments

Since the first approved gene therapy trial in 1990, interest in cell and gene therapies has increased rapidly, changing the course of research on disease prevention and treatment. However, there are still many challenges facing the field today, and further progress to be made in developing effective therapies.

The Advancing CGT Virtual Event is a free, 2-day meeting presented by GENEWIZ and Brooks Life Sciences, offering a platform for industry leaders and researchers from across the globe to discuss the opportunities, challenges, and latest breakthroughs in cell and gene therapy.  Attendees will have the opportunity to learn more about various topics, such as developing AAV-based gene therapies, cold chain products and solutions for a wide range of materials, and more, as well as explore innovative solutions to accelerate the therapeutic development and safe delivery of successful cell and gene therapies.

By registering for the event, attendees can:

  • Watch exciting webinars presented by cell and gene therapy experts and covering a variety of topics from the comfort of your desk.
  • Peruse booths in the virtual exhibit hall to learn more about featured products and services, watch presentations, download literature, and more.
  • Access content on the platform 24/7 for up to 1 year following the completion of the event.

Use the official event hashtag #AdvCGT21 to join the conversation and stay up to date on the latest event information


Speakers

Show Resources
Agenda
  • Functional Roles of the Novel Membrane-Associated AAV Protein MAAP
    APR 08, 2021 2:15 PM EDT
    Functional Roles of the Novel Membrane-Associated AAV Protein MAAP
    Lionel Galibert, Ph.D.
    Senior Scientist, Kuopio Center for Gene and Cell Therapy
  • Cryopreservation and Logistics of Advanced Therapy Medicinal Products: A Cold Subject Suddenly Becomes a Hot Topic
    APR 08, 2021 1:00 PM EDT
    Cryopreservation and Logistics of Advanced Therapy Medicinal Products: A Cold Subject Suddenly Becomes a Hot Topic
    Brian J. Hawkins, Ph.D.
    Chief Technology Officer, Pluristyx, Inc.
  • Using Single-Cell Multiomics to Accelerate Cancer Immune Cell Therapy Research
    APR 08, 2021 10:00 AM EDT
    Using Single-Cell Multiomics to Accelerate Cancer Immune Cell Therapy Research
    Adriana Suarez, Ph.D.
    Science and Technology Advisor, 10x Genomics
  • APR 07, 2021 2:15 PM EDT
    Gene Editing Validation with Highly-Accurate HiFi Reads
    Michael Weiand, Andrea O'Hara, Ph.D.
    Michael Weiand
    Field Applications Manager, AMR East for Pacific Biosci...
    Andrea O'Hara, Ph.D.
    Technical Application Scientist, GENEWIZ, A Brooks Life...
  • Innovative Genomics & Cold Chain Solutions for Development of Cell and Gene Therapies
    APR 07, 2021 1:00 PM EDT
    Innovative Genomics & Cold Chain Solutions for Development of Cell and Gene Therapies
    Elizabeth Louie, Ph.D.
    Supervisor, Technical Applications, GENEWIZ, A Brooks Life Sciences Company
  • Linear DNA: Improving rAAV Production with Synthetic DNA
    APR 07, 2021 10:00 AM EDT
    Linear DNA: Improving rAAV Production with Synthetic DNA
    Jude Samulski, Ph.D.
    President, Chief Scientific Officer and Co-Founder, AskBio
Speakers

  • Lionel Galibert, Ph.D.
    Senior Scientist, Kuopio Center for Gene and Cell Therapy
    Biography

      Dr. Lionel Galibert has accumulated over 15 years of experience in the adeno-associated virus (AAV) gene therapy field. On the team of Dr. Otto Wilhelm Merten in Genethon, France, he helped develop a single baculovirus to produce rAAV8 in Sf9 cells, as well as demonstrated the involvement of the baculovirus protease on the degradation of certain AAV capsids. Dr. Galibert then worked within Dr. Michael Linden's group at Pfizer in London, and was involved in the development of the rAAV production system in fixed-bed bioreactors using mammalian cells. For the last 4 years, Dr. Galibert worked in Kuopio's biotech environment with positions in FinVector and its sister company Kuopio Center for Gene and Cell therapy. Now working in Dr. Kari Airenne's group, he leads their AAV research with a particular focus on the wild-type AAV. He will be presenting the work they performed on the novel AAV protein “Membrane-Associated Accessory Protein” MAAP.

    • Brian J. Hawkins, Ph.D.
      Chief Technology Officer, Pluristyx, Inc.
      Biography

        Dr. Brian Hawkins is the chief technology officer at Pluristyx, Inc., an advanced therapy tools company providing seamless client support to cell therapy groups through CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD™) Pluripotent Stem and Ready-to-Use (RTU™) Differentiated Cells. Dr. Hawkins received his Ph.D. in molecular cell biology and biotechnology from Virginia Tech and completed his postdoctoral training at the University of Pennsylvania, after which he moved to the University of Washington School of Medicine to serve as an assistant professor and founding member of the Mitochondria and Metabolism Center. Dr. Hawkins transitioned to industry and served as the scientific applications director at BioLife Solutions, where he aided numerous commercial groups in optimizing cryopreservation protocols for their cell therapy products. Dr. Hawkins joined Pluristyx in 2019 and continues to provide cryopreservation expertise through both consulting and wet-bench contract development services.  Dr. Hawkins is an internationally recognized cryopreservation expert and has delivered over 20 cryopreservation and/or cell therapy manufacturing-related invited presentations. Dr. Hawkins is an active member of the International Society for Cell and Gene Therapy and the Parenteral Drug Association, where he serves as the president of the Pacific Northwest Chapter, team leader for the PDA Cryopreservation Standards Initiative, and as members of the Biopharmaceutical and Advanced Therapy Medicinal Product Advisory Boards.

      • Elizabeth Louie, Ph.D.
        Supervisor, Technical Applications, GENEWIZ, A Brooks Life Sciences Company
        Biography

          Dr. Elizabeth Louie is the supervisor of the technical applications team at GENEWIZ. She received her Ph.D. in molecular and cellular pharmacology from Stony Brook University. Dr. Louie provides consultation to customers across all genomics solutions that GENEWIZ offers, including next generation sequencing, gene and DNA synthesis, and any custom molecular biology needs.

        • Andrea O'Hara, Ph.D.
          Technical Application Scientist, GENEWIZ, A Brooks Life Sciences Company
          Biography

            Dr. Andrea O’Hara has over 11 years of experience in next generation sequencing. She earned her Ph.D. from the University of North Carolina at Chapel Hill in genetics and molecular biology. She is currently a technical application scientist at GENEWIZ within the NGS team.

          • Jude Samulski, Ph.D.
            President, Chief Scientific Officer and Co-Founder, AskBio
            Biography

              Dr. Samulski received his Ph.D. in medical microbiology and immunology from the University of Florida. His graduate work (1978-82) demonstrated the first use of AAV2 as a viral vector which culminated in the first U.S. FDA approved gene therapy drug for Leber Congenital Amaurosis (LCA). After completing post-doctoral training at Princeton, Dr. Samulski was hired at University of Pittsburgh where his lab demonstrated the first use of AAV for gene delivery to the CNS which eventually led to the initial treatment of AAV for Canavan’s disease. In 1993, he was recruited to University of North Carolina (UNC) to initiate, build and direct the UNC Gene Therapy Center. In this setting, development of self-complementary AAV vectors (currently used in approved SMA gene therapy drug), Chimeric AAV capsids (first example of synthetic vector used in humans - DMD trial), and critical research that enabled large scale production was carried out. Research headed by Dr. Xiao Xiao, Ph.D., demonstrated the first AAV-mediated long-term gene transduction in muscle (J. Virology, 1996). This finding precipitated efforts to develop 1st generation AAV vectors to treat Duchenne muscular dystrophy that is now in Phase 3 clinical trials.

              In total, Dr. Samulski has worked with AAV for 40 years, and for 25 years, he was director of the University of North Carolina Gene Therapy Center. He was the scientific founder of Bamboo Therapeutics, Inc. and served as the Chief Scientific Officer and Executive Chairman of the company until its acquisition by Pfizer in 2016. Upon its acquisition, Dr. Samulski joined Pfizer, as VP Gene Therapy, to ensure the successful transition of Bamboo’s Duchenne muscular dystrophy therapeutic. Dr. Samulski is a former member of the Recombinant DNA Advisory Committee (RAC), a committee tasked with assisting the FDA with gene therapy clinical trial approvals in the U.S. He also frequently serves as a gene therapy consultant to the FDA. In 2008, Dr. Samulski was recognized by the American Society of Cell and Gene Therapy with their inaugural Outstanding Achievement Award for his work and later served as President of the Society. He was also invited by Pope Francis to the Vatican in recognition for his work in the treatment of Canavan’s disease.

              Dr. Samulski has advanced therapeutics into human clinical trials for hemophilia, Duchenne muscular dystrophy, giant axonal neuropathy, Pompe disease and congestive heart failure, to name a few. He has published more than 450 articles and holds more than 300 patents related to AAV technology. Currently, Dr. Samulski is professor in the Department of Pharmacology at UNC and founder and member of Columbus Children’s Foundation that has focused on developing AAV gene therapies for “ultra-rare” disorders.

            • Adriana Suarez, Ph.D.
              Science and Technology Advisor, 10x Genomics
              Biography

                Dr. Adriana Suarez is a science and technology advisor at 10x Genomics, where she helps researchers adopt single-cell and spatial technologies to address their scientific questions. She has worked on a wide range of genomics projects in plants and humans. For her Ph.D. at the University of British Columbia, Dr. Suarez explored how different genomic backgrounds affect gene function and expression. She is a strong supporter of inclusive spaces and led the creation of the 1st genomics hackathon in Canada with a focus on inclusivity.

              • Michael Weiand
                Field Applications Manager, AMR East for Pacific Biosciences
                Biography

                  Mike Weiand has spent almost 8 years with Pacific Biosciences within field applications support, enabling their customers and growing the technology. There he helps manage and assist customers in designing and conducting experiments to initiate and validate the use of the PacBio sequencing in their laboratories. Prior to PacBio, Weiand held research and development roles at Life Technologies and the Broad Institute of MIT and Harvard. While with Life Technologies, his focus was in R&D product development, assay formulation, and designing user workflows of the PGM and Proton systems. At the Broad Institute, he spent over 9 years in technology development and technology exploration, validating, scaling, and implementing next generation sequencing technologies in the high-throughput DNA sequencing platform.

                Help

                General Labroots Questions

                email support@labroots.com  

                Virtual Events and Webinars

                Supported Configurations

                • Operating System Internet Explorer Firefox Chrome Safari
                  Vista IE8+ FF10+ Chrome15+
                  Windows 7 IE8+ FF10+ Chrome15+
                  Windows 8 IE10 FF10+ Chrome15+
                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                • Cookie settings: session cookies enabled
                • Browser configuration must have JavaScript enabled
                • Adobe Flash player 10.2 or later

                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                Internet Connection

                • A minimum of 100Kbps is recommended for audio-only events
                • A minimum of 300Kbps is recommended for speaker on-video events

                Computer Equipment

                • Screen Resolution: Minimum 1024x768
                • Video Card: 65,000 colors minimum
                • Sound card and speakers (or headphones) for hearing webcast in full format
                • Audio Card: 16-bit minimum
                • RAM: 512MB of free RAM

                Firewall Protocol

                • HTTP on port 80 or HTTPS on port 443
                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                Work-At-Home Attendees

                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                For A Seamless Experience

                When using a mobile device, FREE Mobile Apps are available:

                - For viewing Webinars:

                - For viewing Virtual Events

                Attendee Guide

                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                Virtual Event and Webinar Support:

                Continuing Education (CME/CE) Support

                Show Resources
                Attendees
                • See more